Table 1.
Comparison of IC50 values of the anticancer drugs-based metal nanoparticles and their comparison with the free drug.
| Nanoparticle type | Cancer cell line | IC50 value of nanoparticle system | Anticancer drug | IC50 value of free drug | References |
|---|---|---|---|---|---|
| Resveratrol stabilized gold nanoparticles | Glioma carcinoma cell line (LN 229) | 4 μg/mL | Doxorubicin | 6 μg/mL | Mohanty et al. (2014) |
| Multifunctional nanosystem (MFNCs) of gold nanorods, iron oxide nanoparticles, and gold nanoclusters assemblies within BSA nanoparticles | HeLa cancer cells | 2.3 μg/mL | Doxorubicin | 0.5 μg/mL | Pan et al. (2017) |
| Gold nanoparticles based nanoconjugates | Lung cancer cell line (H520) | 25 µM | Docetaxel | 38 µM | Thambiraj et al. (2019) |
| Gold nanoparticles | Breast cancer cells MCF-7 | 30 ± 5 μg/mL | Chloroquine | >30 ± 5 μg/mL | Joshi et al. (2012) |
| Silver nanoparticle | HepG2 cells | 1.92 μg/mL | Epirubicin | 0.11 μg/mL | Ding et al. (2019) |
| Jacalin-capped silver nanoparticles | Human chronic myeloid leukemia | 100 nM | Acetylshikonin (AS) and beta-dimethylacrylshikonin (BDS) | 500 nM | Ayaz Ahmed et al. (2016) |
| PEG capped silver nanoparticles | Breast cancer cells MCF-7 | 258.6 μg/mL | Methotrexate | 512.7 μg/mL | Muhammad et al. (2016) |
| Copper nanoparticles based systems | Drug-resistant prostate cancer cell | 85, 172, and 193 nM | Paclitaxel (control) | 2575 nM | Chen et al. (2018) |